EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vivo Efficacy of a Broad-Spectrum Antiviral Combination Against Yellow Fever in a Hamster Model

Abbie E Weight iD, Hunter Stanger, Robert J Geraghty iD, Laurent F Bonnac iD, Justin G Julander

Pathogens · 2025

DOI: 10.3390/pathogens14090925 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Abbie E Weight und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA. Hauptthemen laut MEDLINE: Yellow Fever, Antiviral Agents, Yellow fever virus, Pyrazines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIAID/NIH, National Institute of Allergy and Infectious Disease, NIH, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yellow fever virus (YFV) recurrently causes severe outbreaks in tropical regions of South America and Africa and an average of 30 to 40 thousand deaths worldwide each year. An effective vaccine is available but the coverage of the population in countries at risk is not optimal. No antivirals are currently approved for YFV treatment. Herein, we describe the evaluation of 6-MMPr, a de-novo-purine-nucleotide biosynthesis inhibitor, as a potentiator for enhanced activity of the broad-spectrum antiviral drug favipiravir in a hamster model of yellow fever. Administration of 6-MMPr was well-tolerated and a combination of favipiravir and 6-MMPr did not cause overt toxicity as indicated by normal weight gain of treated hamsters. Treatment with a combination of a suboptimal dose of favipiravir with 6-MMPr was significantly more effective in improving survival, weight change and virus replication when compared with monotherapy. The initiation of treatment two days after virus challenge was also effective in improving survival when compared with monotherapy. Our results demonstrate the safety and efficacy of such a combination either as a preventive or delayed treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Yellow FeverAntiviral AgentsYellow fever virusPyrazinesAmidesAnimalsCricetinaeDisease Models, AnimalDrug Therapy, CombinationVirus ReplicationMesocricetusTreatment Outcome

Stichwörter der Autor:innen

animal modelbroad-spectrumdrug combinationfavipiravirflavivirusespandemic preparednessyellow fever

Substanzen

Antiviral AgentsfavipiravirPyrazinesAmides

Autor:innen und Institutionen

  • Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA.
  • Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.

ORCID-Profile: Abbie E Weight, Robert J Geraghty, Laurent F Bonnac

Förderung

  • NIAID NIH HHS
  • NIAID/NIH
  • National Institute of Allergy and Infectious Disease, NIH, USA

Zitieren

APA

Weight, A. E., Stanger, H., Geraghty, R. J., Bonnac, L. F., & Julander, J. G. (2025). In Vivo Efficacy of a Broad-Spectrum Antiviral Combination Against Yellow Fever in a Hamster Model. Pathogens. https://doi.org/10.3390/pathogens14090925

Vancouver

Weight AE, Stanger H, Geraghty RJ, Bonnac LF, Julander JG. In Vivo Efficacy of a Broad-Spectrum Antiviral Combination Against Yellow Fever in a Hamster Model. Pathogens. 2025. doi:10.3390/pathogens14090925

BibTeX
@article{Weight2025,
  author = {Weight, Abbie E and Stanger, Hunter and Geraghty, Robert J and Bonnac, Laurent F and Julander, Justin G},
  title = {In Vivo Efficacy of a Broad-Spectrum Antiviral Combination Against Yellow Fever in a Hamster Model},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14090925}
}
Kostenlos starten →